RNAi Drug Delivery Market
完整報告名稱與涵蓋範圍
RNAi Drug Delivery Market Size, Share & Trends Analysis By Target Disease ( Cancer, Metabolic Diseases, Genetic Disorders, Viral Infections, Others), By Technology (miRNA, siRNA, shRNA, Others), By Targeted Tissue (Heart, Brain, Liver, Lungs, Others), By Delivery System (Nanoparticle Drug Delivery Technology, Aptamer Drug Delivery Technology, Pulmonary Drug Delivery Technology, Nucleic Acid Drug Delivery Technology), By Route of Administration (Oral, Intramuscular, Intravenous, Local Injection, Subcutaneous), By End-User), by Region, And by Segment Forecasts, 2025-2034
報告摘要
The worldwide RNAi Drug Delivery Market stood at USD 108.8 Bn in 2024, and is projected to reach USD 559.6 Bn by 2034, recording a CAGR of 18.1% from 2025 through 2034.
RNAi Drug Delivery encompasses challenges.
Market momentum is supported by expanding appetite for advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global RNAi Drug Delivery Market Snapshot
Chapter 4. Global RNAi Drug Delivery Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global RNAi Drug Delivery Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on RNAI DRUG DELIVERY MARKET Industry Trends
Chapter 5. RNAi Drug Delivery Market Segmentation 1: By Technology, Estimates & Trend Analysis
5.1. Market Share by Technology, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology:
5.2.1. siRNA
5.2.2. miRNA
5.2.3. shRNA
5.2.4. Others
Chapter 6. RNAi Drug Delivery Market Segmentation 2: By Target Disease, Estimates & Trend Analysis
6.1. Market Share by Target Disease, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following
Target Disease:
6.2.1. Cancer
6.2.2. Viral Infections
6.2.3. Genetic Disorders
6.2.4. Metabolic Diseases
6.2.5. Other Diseases
Chapter 7. RNAi Drug Delivery Market Segmentation 3: By Delivery System, Estimates & Trend Analysis
7.1. Market Share by Delivery System, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery System:
7.2.1. Nanoparticle Drug Delivery Technology
7.2.2. Pulmonary Drug Delivery Technology
7.2.3. Nucleic Acid Drug Delivery Technology
7.2.4. Aptamer Drug Delivery Technology
Chapter 8. RNAi Drug Delivery Market Segmentation 4: By Targeted Tissue, Estimates & Trend Analysis
8.1. Market Share by Targeted Tissue, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Targeted Tissue:
8.2.1. Liver
8.2.2. Lungs
8.2.3. Brain
8.2.4. Heart
8.2.5. Others
Chapter 9. RNAi Drug Delivery Market Segmentation 5: By Route of Administration, Estimates & Trend Analysis
9.1. Market Share by Route of Administration, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
9.2.1. Intravenous
9.2.2. Intramuscular
9.2.3. Subcutaneous
9.2.4. Local Injection
9.2.5. Oral
Chapter 10. RNAi Drug Delivery Market Segmentation 6: By End User, Estimates & Trend Analysis
10.1. Market Share by End User, 2024 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
10.2.1. Pharmaceutical Companies
10.2.2. Biotechnology Companies
10.2.3. Contract Research Organizations (CROs)
10.2.4. Academic and Research Institutions
10.2.5. Government and Regulatory Bodies
Chapter 11. RNAi Drug Delivery Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. Global RNAi Drug Delivery Market, Regional Snapshot 2024 & 2034
11.2. North America
11.2.1. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.2.1.1. US
11.2.1.2. Canada
11.2.2. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
11.2.3. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Target Disease, 2021-2034
11.2.4. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
11.2.5. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Targeted Tissue, 2021-2034
11.2.6. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
11.2.7. North America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.3. Europe
11.3.1. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.3.1.1. Germany
11.3.1.2. U.K.
11.3.1.3. France
11.3.1.4. Italy
11.3.1.5. Spain
11.3.1.6. Rest of Europe
11.3.2. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
11.3.3. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Target Disease, 2021-2034
11.3.4. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
11.3.5. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Targeted Tissue, 2021-2034
11.3.6. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
11.3.7. Europe RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.4. Asia Pacific
11.4.1. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.4.1.1. India
11.4.1.2. China
11.4.1.3. Japan
11.4.1.4. Australia
11.4.1.5. South Korea
11.4.1.6. Hong Kong
11.4.1.7. Southeast Asia
11.4.1.8. Rest of Asia Pacific
11.4.2. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
11.4.3. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Target Disease, 2021-2034
11.4.4. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
11.4.5. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts By Targeted Tissue, 2021-2034
11.4.6. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
11.4.7. Asia Pacific RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.5. Latin America
11.5.1. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.5.1.1. Brazil
11.5.1.2. Mexico
11.5.1.3. Rest of Latin America
11.5.2. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
11.5.3. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Target Disease, 2021-2034
11.5.4. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
11.5.5. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Targeted Tissue, 2021-2034
11.5.6. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
11.5.7. Latin America RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.6. Middle East & Africa
11.6.1. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.6.1.1. GCC Countries
11.6.1.2. Israel
11.6.1.3. South Africa
11.6.1.4. Rest of Middle East and Africa
11.6.2. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
11.6.3. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Target Disease, 2021-2034
11.6.4. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Delivery System, 2021-2034
11.6.5. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by Targeted Tissue, 2021-2034
11.6.6. Middle East & Africa RNAi Drug Delivery Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Alnylam Pharmaceuticals
12.2.1.1. Business Overview
12.2.1.2. Key Product/Service
12.2.1.3. Financial Performance
12.2.1.4. Geographical Presence
12.2.1.5. Recent Developments with Business Strategy
12.2.2. Arrowhead Pharmaceuticals
12.2.3. Arcturus Therapeutics
12.2.4. Bayer
12.2.5. BioNTech
12.2.6. Dicerna Pharmaceuticals
12.2.7. Ionis Pharmaceuticals
12.2.8. Moderna Therapeutics
12.2.9. Novartis
12.2.10. Pfizer
12.2.11. Roche
12.2.12. Regeneron Pharmaceuticals
12.2.13. Sanofi
12.2.14. Takeda Pharmaceutical
12.2.15. Viridian Therapeutics
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們